Bank of Nova Scotia Sells 3,275 Shares of Danaher Corporation $DHR

Bank of Nova Scotia lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 1.6% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 202,353 shares of the conglomerate’s stock after selling 3,275 shares during the period. Bank of Nova Scotia’s holdings in Danaher were worth $38,366,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Danaher in the fourth quarter worth about $2,177,106,000. Viking Global Investors LP grew its holdings in Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after buying an additional 2,455,994 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Danaher by 104.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after buying an additional 2,216,789 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Finally, Capital International Investors lifted its holdings in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.3%

NYSE DHR opened at $191.87 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a market capitalization of $134.88 billion, a price-to-earnings ratio of 34.08, a PEG ratio of 2.40 and a beta of 0.79. The company has a fifty day moving average of $185.64 and a two-hundred day moving average of $197.04.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, July 21st. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the business earned $0.77 EPS. The business’s revenue was up 5.5% on a year-over-year basis. On average, analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a yield of 0.8%. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: J.P. Morgan reiterated a Buy rating on Danaher, which may help support investor confidence after the post-earnings pullback. J.P. Morgan Keeps Their Buy Rating on Danaher (DHR)
• Positive Sentiment: Several articles argue Danaher’s recent slump looks like an overreaction and could be a buying opportunity, suggesting the stock may recover if investors refocus on its long-term fundamentals. Here’s Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
• Positive Sentiment: Danaher’s quarterly results beat estimates, with EPS of $1.94 versus $1.85 expected and revenue of $6.27 billion above forecasts, which supports the case that core business performance remains solid. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Billionaire investor Dan Loeb reduced his Danaher stake in Q1 2026, adding to sentiment pressure around life sciences tools stocks, though it does not change Danaher’s operating results. Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools Bets
• Neutral Sentiment: Danaher saw unusually heavy put option activity, signaling traders are hedging against more downside in the near term. Don’t Quit on Danaher Stock After Horrific Earnings Reaction

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Argus reduced their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Wells Fargo & Company cut their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday. The Goldman Sachs Group reduced their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Robert W. Baird dropped their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, DZ Bank initiated coverage on Danaher in a report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.